Article
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Osaka city medical journal - 1 Jun 2012
Suzumura Tomohiro, Kimura Tatsuo, Kudoh Shinzoh, Umekawa Kanako, Nagata Misato, Tanaka Hidenori, Mitsuoka Shigeki, Yoshimura Naruo, Kira Yukimi, Hirata Kazuto
Abstract excerpt
BACKGROUND: Rash, liver dysfunction, and diarrhea are known as adverse events of erlotinib and gefitinib. However, clinical trials with gefitinib have reported different adverse events compared to those with erlotinib. In an in vitro study, cytochrome P450 (CYP) 2D6 was shown to be involved in the metabolism of gefitinib and not of erlotinib. It has been hypothesized that gefitinib therapy results in different...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.